control group:platinum-based doublet chemotherapy + placebo

2 trials

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

Conditions

non-small cell lung cancer, NSCLC

Early Phase 1

A multicentered, double-blind, randomized study of Fuzheng syndrome differentiation treatment combined with chemotherapy as the first-line treatment of driver mutation-negative advanced NSCLC

Active, not recruitingITMCTR2000003607

Longhua Hospital, Shanghai University of Traditional Chinese Medicinenon-small cell lung cancer, NSCLC

Start: 2020-10-01Updated: 2023-02-20

A multicentered, double-blind, randomized study of Fuzheng syndrome differentiation treatment combined with chemotherapy as the first-line treatment of driver mutation-negative advanced NSCLC

Active, not recruitingChiCTR2000036074

Longhua Hospital, Shanghai University of Traditional Chinese Medicinenon-small cell lung cancer, NSCLC

Start: 2020-10-01Updated: 2020-09-07